CATCH 2023 Meeting Summary: Collaborate & Address Treatment Challenges in Haemophilia-Reference-Cited by-同舟云学术

CATCH 2023 Meeting Summary: Collaborate & Address Treatment Challenges in Haemophilia

Published:2024-01-01 Issue:1 Volume:11 Page:38-46
ISSN:2055-3390
Container-title:The Journal of Haemophilia Practice
language:en
Short-container-title:

Author:

Benson Gary¹^ORCID,Curry Nicola²^ORCID,Fletcher Simon³^ORCID,Gregory Will⁴^ORCID,Harrison Cathy⁵^ORCID,Laffan Mike⁶^ORCID,Lowe Gillian⁷^ORCID,Khair Kate³^ORCID,Kirk Susan⁸,McLaughlin Paul⁹^ORCID,Percy Charles⁷^ORCID,Player Denise¹⁰^ORCID,Whitaker Sarah¹¹^ORCID

Affiliation:

1. Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit , Belfast , Northern Ireland

2. Oxford University Hospitals NHS Foundation Trust , Oxford , UK

3. Haemnet , London , UK

4. Salford Royal Hospital , Salford , UK

5. Royal Hallamshire Hospital , Sheffield , UK

6. Imperial College London , UK

7. University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK

8. Belfast Health and Social Care Trust , Belfast , Northern Ireland

9. Royal Free London NHS Foundation Trust , London , UK

10. Sobi™ , Herne Hill , UK

11. Basingstoke and North Hampshire Hospital , Basingstoke , UK

Abstract

Abstract Access to treatment and healthcare services for people with haemophilia in the United Kingdom (UK) and Republic of Ireland ranks highly by international standards for contemporary haemophilia management. Collaborate & Address Treatment Challenges in Haemophilia (CATCH) is an annual Sobi™ medical education meeting which brings together multidisciplinary haemophilia treaters throughout the UK and Ireland to discuss all aspects of haemophilia management, including associated challenges and unmet need. This report summarises key issues explored and discussed during CATCH 2023, including ‘raising the bar’ in haemophilia care; haemophilia care for women and girls; changing haemophilia treatment paradigms to consider disease impact as well disease severity; bone health and haemophilia; and shared decision-making.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/jhp-2024-0003

Reference39 articles.

1. European Haemophilia Consortium. Haemophilia care in Europe: 2009-2018. Available from https://www.ehc.eu/haemophilia-care-in-europe/ (accessed December 2023).

2. World Federation of Haemophilia. Report on the Annual Global Survey 2021. WFH, 2022. Available from https://www1.wfh.org/publications/files/pdf-2399.pdf (accessed December 2023).

3. Rayment R, Chalmers E, Forsyth K, et al.; British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol 2020; 190(5): 684-695. doi: 10.1111/bjh.16704.

4. Chowdary P. Nonfactor therapies: new approaches to prophylactic treatment of haemophilia. Hamostaseologie 2021; 41(4): 247-256. doi: 10.105/a-1424-7900.

5. European Medicines Agency. First gene therapy to treat severe haemophilia A. Available from https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia (accessed December 2023).